SPL also analyzed the data and wrote the first draft of the manuscript. Specifically, SPL adapted the clinical protocol from the medical literature. The contributions of these authors are correct in the authors’ contributions section of the submission. which funded this study performed at CUBRC, Inc. SPL wrote the first draft of the manuscript with input from Aethlon employee CJF.Ĭompeting interests: SPL and CJF are employees and receive salaries from Aethlon Medical, Inc. Aethlon employees SPL and CJF analyzed the data.
funded the experiment, which was performed at CUBRC, Inc. SPL, an employee at Aethlon Medical, Inc, adapted the clinical study from the medical literature. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the manuscript.įunding: This study was funded by the sponsor Aethlon Medical, Inc. Received: Accepted: JPublished: July 28, 2022Ĭopyright: © 2022 Gooldy et al. PLoS ONE 17(7):Įditor: Hana Maria Dobrovolny, Texas Christian University, UNITED STATES Extrapolation indicated that an adult Aethlon Hemopurifier® would have more than sufficient binding capacity for viral loads observed in adult patients with severe COVID-19 infection.Ĭitation: Gooldy M, Roux CM, LaRosa SP, Spaulding N, Fisher CJ Jr (2022) Removal of clinically relevant SARS-CoV-2 variants by an affinity resin containing Galanthus nivalis agglutinin. Viral capture efficiency was found to range from 53 to 89% for all variants. Percent decrease in viral titer was compared with a control sample. Known concentrations of seven clinically relevant SARS-CoV-2 variants were spiked in medium and passed three times over columns containing 1 gm of GNA affinity resin. We hypothesized that viral binding should be unaffected by spike protein mutations. The plant lectin Galanthus nivalis binds to mannose structures in the viral envelope. Resistance to vaccination and limitations in the current treatments available require the ongoing development of therapies especially for those with severe disease. The pandemic has been characterized by the development of a succession of variants containing mutations in the spike protein affecting infectiousness, virulence and efficacy of vaccines and monoclonal antibodies. The Coronavirus -19 (COVID-19) pandemic due to the SARS-CoV-2 virus has now exceeded two years in duration.
0 kommentar(er)
